Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Biomaterials. 2021 Oct 13;279:121184. doi: 10.1016/j.biomaterials.2021.121184

Figure 6: TGFβ inhibitor-loaded ICB-ANCs improve anti-tumor effects of i.t. combination immunotherapy in B16F10 melanoma model.

Figure 6:

A) Fraction of initial loaded SB-431542 (TGFβi, starting concentration 4 mM) amount remaining in NP during in vitro release with dialysis. B) B16F10 tumor growth in response to i.t. treatment on day 5, 7, 9, 11, and 13 post tumor implantation with ICB- [aPD1 (6 μg total mAb dose) and aCTLA4 (6 μg total mAb dose)] ANCs co-encapsulating TGFβi or co-injected with isotype-ANCs encapsulating TGFβi (5 μg total dose). ICB-ANCs consisted of an equal mixture of ANCs functionalized with either aPD1 or aCTLA-4. Each tumor growth curve ends on the day of the first animal death. C) Tumor volume on day 15 post-implant. D) Survival curves of animals whose tumor volumes are shown in (B). Statistical analyses were done using two- (B) or one-way (C) ANOVA with Tukey’s test. Log-rank (Mantel-Cox) test for survival curve (D). **p < 0.01, ***p < 0.001.